| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Myelin-specific CD4+ T cells (Th1 and Th17 subsets). MOG (35-55) functions as an immunodominant epitope presented by the MHC class II molecule I-Ab to CD4+ T cells. This activation triggers the differentiation of naive T cells into pro-inflammatory effector cells, which mediate CNS inflammation and demyelination.
|
|---|---|
| ln Vitro |
Myelin Oligodendrocyte Glycoprotein Peptide (35–55), rat and mouse acetate (0–50 μg/mL; 72 hours; lymph node cells) stimulates T cell proliferation and secretes Th1 cytokines, such as IL-10, IL-4, IL-5, TNF-α, and IFN-γ. IgG levels can be raised by mouse and rat acetate, myelin oligodendrocyte glycoprotein peptide (35–55), and other sources [1].
In vitro, MOG (35-55) acetate stimulates the proliferation of MOG-specific T cells isolated from the lymph nodes of immunized mice. At concentrations between 0-50 microg/mL, it induces a robust proliferative response and triggers the secretion of a panel of pro-inflammatory Th1/Th17 cytokines, including IFN-gamma, TNF-alpha, IL-17A, and GM-CSF. It also enhances the production of anti-MOG IgG antibodies. |
| ln Vivo |
In HLA-DR2 (DRB1*1501) mice, myelin Oligodendrocyte Glycoprotein Peptide (35–55), mouse, and rat acetate (200 μg (0.2 mL); intraperitoneally; once for 38 days) exhibits encephalitogenic activity[1].
In vivo, the acetate salt of MOG (35-55) is a potent inducer of EAE. When emulsified in Complete Freund's Adjuvant (CFA) and administered subcutaneously with pertussis toxin (PTX) as an additional adjuvant, it produces a relapsing-remitting or chronic-progressive neurological disease characterized by extensive plaque-like demyelination. The clinical symptoms include tail weakness, paraparesis, and eventual paralysis, mimicking human MS. |
| Enzyme Assay |
Non-cellular binding assays are not standard for this peptide immunogen. Its mode of action requires processing and presentation by living antigen-presenting cells. However, a direct binding assay to the purified MHC class II molecule (I-Ab) can be performed. In this competitive assay, purified I-Ab is immobilized, and a labeled high-affinity peptide is used as a tracer. Unlabeled MOG (35-55) is added to compete, and the IC50 for binding is determined using a homogeneous time-resolved fluorescence (HTRF) or surface plasmon resonance (SPR) detection system.
|
| Cell Assay |
The T cell proliferation assay is the standard in vitro method. Lymph node cells (LNCs) are harvested from mice 10-14 days after immunization with MOG (35-55) and cultured in 96-well plates. The cells are re-stimulated with various concentrations of MOG (35-55) acetate (e.g., 0, 5, 10, 50 microg/mL) for 48-72 hours. Proliferation is measured by [3H]-thymidine incorporation, which is added during the final 16-18 hours of culture. The stimulation index (SI) is calculated as the ratio of cpm in stimulated wells to cpm in unstimulated wells. Cytokine levels in the culture supernatants are measured by ELISA.
|
| Animal Protocol |
Animal/Disease Models: HLA-DR2 (DRB1*1501) mice[1]
Doses: 200 μg (0.2 mL) Route of Administration: intraperitoneal (ip)injection; once, for 38 days Experimental Results: Resulted in paralysis of both hind and forelimbs. The standard EAE induction protocol for C57BL/6 mice involves the following steps: On day 0, a 200 microL emulsion containing 200-300 microg of MOG (35-55) acetate and an equal volume of Complete Freund's Adjuvant (CFA) supplemented with 4 mg/mL of Mycobacterium tuberculosis is injected subcutaneously (s.c.) in the flank. Additionally, mice receive an intraperitoneal (i.p.) injection of 200 ng of Pertussis toxin (PTX) on day 0 and again on day 2. Mice are monitored daily for body weight loss and clinical signs of EAE (scored on a 0-5 scale). The experiment typically concludes at day 30-40, at which point the spinal cord and brain are processed for histology to assess demyelination and inflammatory cell infiltration. |
| ADME/Pharmacokinetics |
The peptide itself is a short polypeptide that is rapidly cleared and processed. Therefore, its own pharmacokinetic (PK) parameters are not relevant in the context of EAE induction. The disease pathology is driven by the adaptive immune response, which takes days to develop. The "half-life" of the disease is measured in weeks, not hours, and reflects the persistence of the autoreactive T cells and the ongoing demyelination.
|
| Toxicity/Toxicokinetics |
The primary toxicological endpoint of MOG (35-55) acetate is the induction of EAE, which is the intended outcome of the study. The autoimmune response leads to severe clinical symptoms, including debilitating paralysis, weight loss, and potential mortality. While this is a valuable research model, it is essential to strictly follow animal welfare protocols, including humane endpoints, to mitigate suffering. The peptide itself is not acutely toxic at the administered doses.
|
| References |
|
| Additional Infomation |
The acetate salt is an alternative salt form to the more common TFA salt. The choice between TFA and acetate can be important for certain in vivo applications, as TFA can be toxic in some animal models if present in high amounts. The acetate form, therefore, may be preferred when injecting high doses or performing repeat-dose studies. MOG (35-55) is the most widely used antigen to induce EAE in C57BL/6 mice, the most common mouse strain for genetic studies (e.g., using knockouts), making it an indispensable tool for studying the mechanisms of autoimmune demyelinating diseases.
|
| Molecular Formula |
C120H181N35O31S
|
|---|---|
| Molecular Weight |
2642.00
|
| Related CAS # |
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA;Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat;149635-73-4
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~37.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3785 mL | 1.8925 mL | 3.7850 mL | |
| 5 mM | 0.0757 mL | 0.3785 mL | 0.7570 mL | |
| 10 mM | 0.0379 mL | 0.1893 mL | 0.3785 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
